Anna Barry, PhD, is a life sciences executive with over two decades of experience in the biotechnology industry with expertise in strategy, corporate development, operations, financing, business development, and intellectual property. She has been a member of senior management teams that successfully led companies through organizational growth and transformation, including company’s evolution from a privately held, discovery stage start-up to a publicly traded, development stage biotechnology company. Dr. Barry currently serves as a venture partner at Deerfield Management. Previously she was the chief operating officer at Korro Bio, a next generation RNA editing company. Prior to Korro Bio, Dr. Barry was senior vice president and general counsel at Jounce Therapeutics, head of intellectual property at Five Prime Therapeutics, and senior patent counsel at Genentech. Dr. Barry received her BS in Chemistry from the Georgia Institute of Technology, PhD in Biophysical Chemistry from Yale University, and a JD from Vanderbilt University.